Advanced Drug Delivery Reviews

Article	Citations
Editorial board members	960
Drug delivery for metabolism targeted cancer immunotherapy	345
Recent advances in endocrine organoids for therapeutic application	295
Emerging strategies to bypass transplant rejection via biomaterial-assisted immunoengineering: Insights from islets and beyond	264
Cell membrane-coated nanoparticles for targeting carcinogenic bacteria	241
Long-acting inhaled medicines: Present and future	223
Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles	216
Covalent chemistry in targeted protein degradation	212
Luminescent quantum dots: Synthesis, optical properties, bioimaging and toxicity	211
Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders	210
Nanoparticle-neutrophils interactions for autoimmune regulation	210
Progress on the pathological tissue microenvironment barrier-modulated nanomedicine	196
Bacterially mediated drug delivery and therapeutics: Strategies and advancements	189
MIDD in Japan– Implementations, challenges and opportunities	188
Deciphering albumin-directed drug delivery by imaging	184
Liposomal formulations for treating lysosomal storage disorders	181
Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses	178
Emerging antibiotic alternatives: From antimicrobial peptides to bacteriophage therapies	175
Penetration and translocation of functional inorganic nanomaterials into biological barriers	173
Genome-scale metabolic modelling in antimicrobial pharmacology: Present and future	167
Opportunities and challenges in delivering biologics for Alzheimer’s disease by low-intensity ultrasound	166
Integrating microneedles and sensing strategies for diagnostic and monitoring applications: The state of the art	164
Models to study basic and applied aspects of lysosomal storage disorders	163
Leveraging the neurosurgical operating room for therapeutic development in NeuroOncology	159
In vitro models of the interplay between glioblastoma and blood–brain barrier for stratifying drug efficacy	157

Editorial Board	153
Protein encapsulation of nanocatalysts: A feasible approach to facilitate catalytic theranostics	146
Nanoparticles-mediated ion channels manipulation: From their membrane interactions to bioapplications	145
Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders	143
Synthetic biology-guided design and biosynthesis of protein polymers for delivery	139
Editorial/Preface	138
Targeting microbiome, drug metabolism, and drug delivery in oncology	137
Emerging Voices in Drug Delivery – Harnessing and Modulating Complex Biological Systems (Issue 2)	136
3D printing of drug delivery systems enhanced with micro/nano-technology	132
Drug delivery using gold nanoparticles	128
Activatable fluorescent probes for real-time imaging-guided tumor therapy	126
Strategies to develop polymeric microneedles for controlled drug release	126
From cells to subcellular organelles: Next-generation cancer therapy based on peptide self-assembly	120
Hydrogen sulfide in cancer therapy: Intelligent delivery platforms and synergistic therapeutic paradigms	118
Activatable dual-functional molecular agents for imaging-guided cancer therapy	118
Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer’s disease	117
iPSC-derived T cells and macrophages: Manufacturing and next-generation application approaches	116
Solid implantable devices for sustained drug delivery	115
RNA binding proteins (RBPs) and their role in DNA damage and radiation response in cancer	114
In situ cellular hitchhiking of nanoparticles for drug delivery	112
Red to near-infrared carbon dots: synthesis, cellular interactions, drug loading, and therapeutic applications	110
Quality by Computational Design: Harnessing AI to Advance Rational Drug Development	109
Pulmonary delivery nanomedicines towards circumventing physiological barriers: Strategies and characterization approaches	109
Novel strategies for modulating the gut microbiome for cancer therapy	106
Small data, big challenges: Machine- and deep-learning strategies for data-limited drug discovery	106
Biopharmaceutical drug delivery and phototherapy using protein crystals	105
Therapeutic gases as emerging treatments for oral diseases	105
Engineering complexity in human tissue models of cancer	104
Advances in photoactivated carbon-based nanostructured materials for targeted cancer therapy	104
Technology for Nucleic Acid Delivery in the Treatment of Hematological Malignancies	102
Lysosomal therapies and drug delivery strategies: An overview	102
Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer	101
Hurdles in translating science from lab to market in delivery systems for Cosmetics: An industrial perspective	100
Tumour extravasation of nanomedicine: The EPR and alternative pathways	100
Tumor microenvironment subtyping in pancreatic ductal adenocarcinoma: New avenues for personalized therapeutic strategies	100
Novel drug delivery systems for the management of dry eye	98
Micro-patterned cell populations as advanced pharmaceutical drugs with precise functional control	98
Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies	97
Convection-enhanced delivery for brain malignancies: Technical parameters, formulation strategies and clinical perspectives	97
Nanobodies: Robust miniprotein binders in biomedicine	95
Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers	94
Miniaturized therapeutic systems for ultrasound-modulated drug delivery to the central and peripheral nervous system	94
Soft nano and microstructures for the photomodulation of cellular signaling and behavior	93
Matrix-integrated microfluidic tumor models for evaluating drug delivery systems and pre-clinical testing	92
Nanosensitizer-mediated unique dynamic therapy tactics for effective inhibition of deep tumors	92
Unignored intracellular journey and biomedical applications of extracellular vesicles	92
Light sheet fluorescence microscopy for monitoring drug delivery: Unlocking the developmental phases of embryos	91
Emerging drug delivery systems with traditional routes – A roadmap to chronic inflammatory diseases	90
Fit and forget: The future of dental implant therapy via nanotechnology	90
Lipid nanoparticles for targeted delivery of anticancer therapeutics: Recent advances in development of siRNA and lipoprotein-mimicking nanocarriers	90

Model-informed precision dosing: State of the art and future perspectives	90
Preface: Image-assisted organoid research and application	89
Editorial Board	89
Nanoparticle-based immunotherapeutics: From the properties of nanocores to the differential effects of administration routes	88
Editorial Board	88
MicroRNA-targeting nanomedicines for the treatment of intervertebral disc degeneration	87
Oral nanomedicine biointeractions in the gastrointestinal tract in health and disease	87
Editorial board members	86
Design of disintegrable nanoassemblies to release multiple small-sized nanoparticles	86
Corrigendum to “Editorial: Advanced strategies to bridge the gap between inflammation and tissue regeneration” [Adv. Drug Deliv. Rev. 209 (2024) 115328]	85
Design principles for construction of DNA-based nanostructures	85
Engineering tissue patterning in human stem cell-based embryo models	85
Editorial board members	85
Molecularly targeted nanomedicine enabled by inorganic nanoparticles for atherosclerosis diagnosis and treatment	85
Modulating tumor physical microenvironment for fueling CAR-T cell therapy	84
Rational modification of PROTACs for tumor-selective protein degradation	84
Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy	83
Gelatin-integrated carbon nanomaterials in nanomedicine: From biosensing and bioprinting to tissue engineering and other biomedical applications	82
Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy	82
Listening to drug delivery and responses via photoacoustic imaging	81
Recent progress in upconversion nanomaterials for emerging optical biological applications	81
Trends and patterns in cancer nanotechnology research: A survey of NCI's caNanoLab and nanotechnology characterization laboratory	81
Beyond the adverse effects of the systemic route: Exploiting nanocarriers for the topical treatment of skin cancers	81
Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood–brain barrier (BBB) to manage neurological disorders	79
Editorial: Subcellular organelle-targeting of nanomaterials for enhancing therapeutic effectiveness	78
Aptamer-based targeted drug delivery and disease therapy in preclinical and clinical applications	78
Medicinal gases for treating central nervous system injuries	77
Investigating the restriction-modification barrier to DNA delivery in human gut probiotic bacteria for streamlined genetic tool development	77
Drug delivery, development, and technological aspects for peripheral drug eluting stents	76
Patient-Derived 3D-Bioprinted Models of Pancreatic Cancer: Toward Personalized Therapy and Overcoming Tumor Microenvironment Challenges	76
Recent advances in intelligent oxygen delivery systems for tissue regeneration	76
Storming the gate: New approaches for targeting the dynamic tight junction for improved drug delivery	75
Additive manufacturing in spatial patterning for spinal cord injury treatment	75
Reversibility and therapeutic development for neurodevelopmental disorders, insights from genetic animal models	74
Omics approaches for the assessment of biological responses to nanoparticles	73
Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins	73
Spectral computed tomography with inorganic nanomaterials: State-of-the-art	72
mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond	72
Editorial Board	72
Progress of engineered bacteria for tumor therapy	72
Intrathecal delivery and its applications in leptomeningeal disease	72
Microbial heterogeneity-mediated treatment evasion and the potential for engineered live biotherapeutic products	72
Integrating PROTAC-based targeted protein degradation with nanodelivery systems to overcome cancer therapeutic resistance	72
Editorial Board	72
Corrigendum to “Advanced theragnostics for the central nervous system (CNS) and neurological disorders using functional inorganic nanomaterials” [Adv. Drug Delivery Rev. 192 (2023) 114636]	71
The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development	71
Applications of pharmacometrics in drug development	70
Stimuli-activatable protein degraders for targeted cancer therapy: from prodrug design to nanoplatform applications	69
3D extrusion bioprinting of microbial inks for biomedical applications	69
Steric stabilization of bioactive nanoparticles using elastin-like polypeptides	68
Delivery and kinetics of immersion optical clearing agents in tissues: Optical imaging from ex vivo to in vivo	67
Nitric oxide-modulating biomaterials for therapeutic Immunoengineering	67
Imaging drug delivery to the lungs: Methods and applications in oncology	67
Recent developments in lactose blend formulations for carrier-based dry powder inhalation	67
Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy	65
Get out or die trying: Peptide- and protein-based endosomal escape of RNA therapeutics	65
Polymer-based nanomedicines: Supporting multimodal approaches to glioblastoma multiforme treatment	63
Nanoarchitectured two-dimensional layered double hydroxides-based nanocomposites for biomedical applications	63
The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives	63
Advances in Salmonella Typhimurium-based drug delivery system for cancer therapy	63
Microbiota and plant-derived vesicles that serve as therapeutic agents and delivery carriers to regulate metabolic syndrome	63
Protein corona: Friend or foe? Co-opting serum proteins for nanoparticle delivery	62
Intranasal and inhaled delivery systems for targeting circadian dysfunction in neurodegenerative disorders, perspective and future outlook	62
Corrigendum to “Light sheet fluorescence microscopy for monitoring drug delivery: unlocking the developmental phases of embryos” [Adv Drug Del. Rev. 218 (2025) 115520]	61
Corrigendum to “Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic” [Adv. Drug Delivery Rev. 179 (2021) 114000]	61
Editorial board members	61
Microbubble-assisted ultrasound for inner ear drug delivery	61
Ocular therapies with biomacromolecules: From local injection to eyedrop and emerging noninvasive delivery strategies	61
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics	61
Revealing the clinical potential of high-resolution organoids	61
Nanomedicine for targeting brain Neurodegeneration: Critical barriers and circadian rhythm Considerations	60
Drug delivery across the blood-brain barrier for the treatment of pediatric brain tumors – An update	60
Progress of tumor-resident intracellular bacteria for cancer therapy	60
Towards artificial intelligence-enabled extracellular vesicle precision drug delivery	60
Laser ablation: Heating up the anti-tumor response in the intracranial compartment	60
Pancreatic organoids as cancer avatars for true personalized medicine	59
The tendon microenvironment: Engineered in vitro models to study cellular crosstalk	59
Sustained delivery approaches to improving adaptive immune responses	59
Biosafety of mesoporous silica nanoparticles; towards clinical translation	59
Next generation concepts in dermal delivery, theranostics, and preclinical testing	58

Biomaterials releasing drug responsively to promote wound healing via regulation of pathological microenvironment	58
Editorial Board	58
Editorial Board	57
Editorial board members	57
Targeted delivery methods for RNA interference are necessary to obtain a potential functional cure for HIV/AIDS	57
Editorial board members	57
Editorial board members	57
Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems	56
The effects of protein corona on in vivo fate of nanocarriers	56
Long-acting parenteral drug delivery systems for the treatment of chronic diseases	56
Stealth and pseudo-stealth nanocarriers	55
Biological and intracellular fates of drug nanocrystals through different delivery routes: Recent development enabled by bioimaging and PK modeling	55
Advances in modular control of CAR-T therapy with adapter-mediated CARs	55
Fungal infections: Immune defense, immunotherapies and vaccines	55
Photonic and magnetic materials for on-demand local drug delivery	54
The RNA-binding protein HuR in human cancer: A friend or foe?	54
Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics	54
Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor	54
Cell-based relay delivery strategy in biomedical applications	53
Advanced oral therapies for colorectal cancer via nanomedicine and microbiota modulation	53
Targeting bacterial metabolites in tumor for cancer therapy: An alternative approach for targeting tumor-associated bacteria	53
Recent applications of three-dimensional bioprinting in drug discovery and development	53
Precise subcellular targeting approaches for organelle-related disorders	53
Synergies between data science methods and innovative drug delivery technologies	53
From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer	53
Theme issue: In vitro mucus models	52
Integrated pharmacokinetic-pharmacodynamic and agent-based modelling in drug development: Current status and future perspectives	52
Biomedical engineering of two-dimensional MXenes	52
Synthetic RNA-based post-transcriptional expression control methods and genetic circuits	51
Current issues in optical monitoring of drug delivery via hair follicles	51
Editorial Board	50
Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids	50
Overcoming barriers and shaping the future: Challenges and innovations in nucleic acid therapies for Glioblastoma	50
Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies	50
Transdermal drug delivery via microneedles to mediate wound microenvironment	50
Mitochondrial endogenous substance transport-inspired nanomaterials for mitochondria-targeted gene delivery	50
Editorial Board	50